- 1 **Title:** Menopausal symptom burden as a predictor of mid- to late-life cognitive function and
- 2 mild behavioral impairment symptoms: A CAN-PROTECT study.
- 3 **Short Title:** Menopausal Symptom Burden
- 4 **Author Names:** Jasper F.E. Crockford^{1,2¶}, Dylan X Guan^{1,3,4¶}, Gillian Einstein^{5,6}, Clive Ballard⁷,
- 5 Bryon Creese⁷, Anne Corbett⁷, Ellie Pickering⁷, Adam Bloomfield⁷, Pamela Roach^{1,8,9}, Eric E
- 6 Smith^{1,2,4,8} Zahinoor Ismail^{1-2,4,7-10*}
- 7 (1) University of Calgary, AB, Canada
- 8 (2) Department of Clinical Neurosciences, University of Calgary, AB, Canada
- 9 (3) Faculty of Graduate Studies, University of Calgary, AB, Canada
- 10 (4) Hotchkiss Brain Institute, University of Calgary, AB, Canada
- 11 (5) Department of Psychology, University of Toronto, ON, Canada
- 12 (6) Rotman Research Institute, Baycrest Hospital, Toronto, ON, Canada
- 13 (7) Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter,
- 14 Exeter, UK

22

- 15 (8) Department of Community Health Sciences, University of Calgary, AB, Canada
- 16 (9) O'Brien Institute for Public Health, University of Calgary, AB, Canada
- 17 (10) Department of Psychiatry, University of Calgary, AB, Canada
- *Corresponding Author:
- 19 Email: ismailz@ucalgary.ca (ZI)
- These authors contributed equally to this work.
- 21 &These authors also contributed equally to this work.

Abstract

24

25 **Background:** Recent evidence suggests the experience of menopausal symptoms (i.e., 26 perimenopausal symptoms) may be associated with cognitive and behavioural changes. We 27 investigated these two relationships in a sample of post-menopausal females. 28 **Design:** Cross-sectional observational study. 29 **Setting:** Participant data was collected from the Canadian Platform for Research Online to 30 Investigate Health, Quality of Life, Cognition, Behaviour, Function, and Caregiving in Aging 31 (CAN-PROTECT) study. 32 **Participants:** 896 post-menopausal female participants. 33 **Methods:** Menopausal symptom burden was operationalized by summing the total number of 34 recalled perimenopausal symptoms experienced. Cognitive function was measured using the 35 Everyday Cognition (ECog-II) Scale, with higher scores reflecting greater severity. Mild 36 Behavioral Impairment (MBI) was measured using the Mild Behavioral Impairment Checklist 37 (MBI-C), with higher scores reflecting greater severity. A negative-binomial regression model 38 examined the relationship between menopausal symptom burden and cognitive function, while a 39 zero-inflated negative binomial regression model examined the relationship between menopausal 40 symptom burden and MBI symptoms. Models adjusted for age, years of education, age of 41 menopausal onset, type of menopause, and hormone therapy (HT). Age of menopausal onset and 42 use of HT in the two associations were investigated with moderation analyses. 43 **Results:** Greater menopausal symptom burden was associated with higher ECog-II total scores 44 (b [95% confidence interval (CI)] = 5.37 [2.85, 7.97]) and higher MBI-C total scores (b [95% CI] 45 = 6.09 [2.50, 9.80]). Use of HT did not significantly associate with ECog-II total scores (b [95%]

- 46 CI] = -10.98 [-25.33, 6.35]), however, HT was significantly associated with lower MBI-C total
- 47 scores (b [95% CI] = -26.90 [-43.35, -5.67]).
- 48 **Conclusions:** Menopausal symptom burden is associated with poorer cognitive function and
- 49 more MBI symptoms in mid- to late life. HT may help mitigate symptoms of MBI. These
- 50 findings suggest the experience of menopause may indicate susceptibility to cognitive and
- 51 behavioural changes, both markers of dementia.

Introduction

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

As the number of older adults continues to rise, those living with Alzheimer's disease (AD) and related dementias globally are estimated to increase three-fold from 50 million in 2015 to 152 million by 2050¹. Females (i.e., assigned female sex at birth) have a three-fold greater risk of developing AD², and will be disproportionately affected by this increasing global dementia burden³. As prevalence of dementia increases with age⁴, the primary explanation offered for the sex discrepancy is greater longevity in females⁵. However, whether longevity alone explains this sex difference remains uncertain; extant literature has proposed there are unique factors that may increase female risk⁴. One proposed factor that may confer special risk to females is the loss of estradiol at menopause. Menopause describes the permanent cessation of menses⁶. There are "many menopauses", each with their own cognitive sequelae⁷, which can occur either spontaneously (i.e., naturally) or due to medical or surgical reasons (e.g., cancer treatments, oophorectomy, hysterectomy) in mid-adulthood⁸. Menopause comprises physiological, cognitive, and behavioural symptoms, likely related to declining 17-b-estradiol (estradiol) levels – the most common type of estrogen⁹. Menopausal symptoms (e.g., poor sleep, depression, etc.) may themselves create risk of later brain pathology, such as the development of AD-related neuropathologies¹⁰⁻¹³. Later-life decline in cognitive function can signal risk of incident dementia^{14,15} and menopause is associated with cognitive changes ^{7,8,16,17}. Recent cross-sectional studies have found spontaneous menopause to be associated with poorer cognitive performance in the domains of language^{18,19}, memory^{8,20-23}, visuo-spatial²⁴, and executive function^{20,24-28}. However, studies have not determined the nature of this association — whether cognition is related to

ovarian cessation, itself, or to an additive effect of multiple menopausal symptoms. Longitudinally, earlier entry into menopause, whether spontaneously or surgically, has been linked to greater risk of cognitive impairment, AD, and other dementias 16,17,29-31. Hormone therapies (HT) composed of estrogen variations and hormonal contraceptives, including oral contraceptive, have long been used to ameliorate menopausal symptoms. However, whether HT use is associated with improvement in cognition or reduced incidence of dementia remains unclear^{8,32-35}. Analogous to cognitive changes, later-life behavioural changes can also signal risk for incident dementia. The International Society to Advance Alzheimer's Research and Treatment's criteria for the syndrome Mild Behavioral Impairment (MBI)³⁶ operationalizes risk by identifying behavioural and neuropsychiatric symptoms (NPS) that are later-life emergent and persistent. NPS meeting these criteria confer significantly higher risk of incident cognitive decline and dementia compared to conventionally measured behavioural and psychiatric symptomatology³⁷⁻⁴⁷ However, unlike the relationship between ovarian cessation (i.e., any type of menopause) and cognition, evidence is sparse on the association between ovarian cessation and MBI. This evidence gap warrants further investigation. We investigated the relationship between menopausal symptoms and later-life changes in cognitive function and behaviour; both risk factors for dementia, which may also represent preclinical/prodromal AD^{14,15,42,43,48-55}. We hypothesized that individuals who experienced a greater number of menopausal symptoms (i.e., greater menopausal symptom burden) would subsequently experience poorer cognitive function and greater MBI symptom burden compared to individuals who experienced fewer menopausal symptoms.

Methods

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

CAN-PROTECT study

Data were collected from the ongoing Canadian Platform for Research Online to Investigate Health, Quality of Life, Cognition, Behaviour, Function, and Caregiving in Aging (CAN-PROTECT) study⁵⁶. CAN-PROTECT is a Canada-wide online observational cohort study of brain aging that seeks to assess the roles of demographic, medical, environmental, and lifestyle factors on risk and resilience. To participate in CAN-PROTECT, individuals must be dementia-free residents of Canada, aged ≥18 years, with access to an internet-connected computer or tablet. In CAN-PROTECT, participants complete a detailed demographics questionnaire, and an annual series of mandatory and optional online assessments of cognition, behaviour, function, health, wellness, quality of life, medical/psychiatric history, and lifestyle. CAN-PROTECT was approved by the Conjoint Health Research Ethics Board at the University of Calgary and began participant recruitment on March 8, 2024. Informed consent was obtained from all participants at registration.

Participants

Baseline participant responses pertaining to demographics, cognition, and emotional/psychiatric symptoms were analyzed, in addition to the optional fertility and menopause questionnaire. From the initial sample of 1984 participants (77.7% female), 896 (100% female) who reported being post-menopausal were included here. Of these, 667 had spontaneous menopause, 162 menopause due to hysterectomy/oophorectomy, and 67 menopause due to other medical reasons (Figure 1).

Figure 1. Flowchart of participants from CAN-PROTECT included for analysis.

Abbreviations: CAN-PROTECT, Canadian Platform for Research Online to Investigate Health,

Quality of Life, Cognition, Behaviour, Function, and Caregiving in Aging.

Measurements

Menopausal symptom burden scale

The recalled presence or absence of 11 perimenopausal symptoms reflecting vasomotor, cognitive, and behavioural/neuropsychiatric symptoms was assessed using the fertility and menopause questionnaire. The scale comprised 11 symptoms including irregular periods, hot flashes, chills, vaginal dryness, weight gain, slowed metabolism, night sweats, sleep problems, mood symptoms, inattention or forgetfulness, and other unnamed symptoms. Total menopausal symptom burden was calculated by summing the number of self-reported menopausal symptoms experienced by participants. Menopausal symptom burden scores ranged from 0 to 11, with 0 representing the least burden (i.e., no symptoms present) and 11 representing the greatest burden (i.e., presence of all 11 symptoms).

Everyday cognition scale

Cognitive function was measured with the revised Everyday Cognition (ECog-II) Scale⁵⁷, developed to identify new onset cognitive symptoms in dementia at-risk populations. The scale consists of 41 questions that assess changes in memory (9 items), language (8 items), visual-spatial and perceptual abilities (8 items), planning (5 items), organization (4 items), and executive function (4 items). Questions are rated from 0-3 (0 = no change, 1 = occasionally worse, 2 = consistently a little worse, 3 = much worse) relative to a participant's own baseline, with higher scores reflecting more consistent impairment. Total ECog-II scores were calculated by summing all item scores. Thus, a higher ECog-II total score indicate worse cognitive function.

Mild Behavioral Impairment checklist

MBI symptoms were assessed using the Mild Behavioral Impairment Checklist (MBI-C)^{58,59}, developed to identify new onset behavioural symptoms in dementia at-risk populations. The MBI-C consists of 34 items that evaluate later-life emergent and persistent neuropsychiatric symptoms in five domains: apathy (6 items), affect (6 items), impulse dyscontrol (12 items), social cognition (5 items), and psychosis (5 items). Like the ECog-II, MBI-C items are scored from 0-3, with higher scores reflecting greater symptom change from baseline. A total MBI symptom burden score was calculated by summing all item responses to create a total out of 102. Higher MBI-C total scores reflected greater MBI symptom burden.

Participant characteristics were summarized using descriptive statistics (count,

Statistical analysis

percentages, mean, and standard deviation). The data were overdispersed counts (i.e., variance>mean). Thus, to assess the relationship between menopausal symptom burden and cognitive function, a negative binomial regression model was used. Menopausal symptom burden was treated as the exposure variable and ECog-II total score as the outcome variable.

Similarly, to assess the relationship between menopausal symptom burden and MBI symptoms, a zero-inflated negative binomial regression model was used. Menopausal symptom burden was treated as the exposure variable and MBI-C total score as the outcome variable. Both models were adjusted for age, total years of education, type of menopause, age of menopausal onset, and use of HT. Type of menopause consisted of two conditions: 1) spontaneous; and 2) due to surgical or medical reasons. Additionally, the use of HT consisted of three conditions: 1) no HT use; 2) use of progestin or unnamed HT forms; and 3) and use of HT. In both models, two interaction terms were included: 1) age of menopausal onset (participant age of menopausal onset was compared to the mean age of menopausal onset); and 2) use of HT.

Results

Of the 896 included participants assigned female sex at birth, 895 identified as women, while one participant identified as two-spirit. The mean (\pm standard deviation; SD) age of participants was 64.2 \pm 7.3 years with 15.5 \pm 5.0 years of education. Participants reported the onset of menopause at a mean age of 49.4 \pm 6.5 years; spontaneous menopause, menopause due to hysterectomy/oophorectomy, and menopause due to other medical reasons occurred at the mean ages of 51.3 \pm 4.2, 42.0 \pm 8.7, and 47.3 \pm 5.2 years, respectively. A total of 666 (74.3%) participants experienced menopausal symptoms. To manage perimenopausal symptoms 166 (24.9%) participants used HT, including estradiol-based therapy (n = 41, 6.2%), conjugated estrogens (n = 34, 5.1%), estrogens-progesterone combinations (n = 73, 11.0%), or estrogens-progestin combinations (n = 18, 2.7%). Twelve participants reported the use of progestin (1.8%) and 47 reported the use of unnamed HT types (7.1%) (see Table 1 for details of participant demographics).

Table 1. Demographic characteristics of participants

Demographic Characteristic	n(%)	M(SD)	Range(years - years)
Sex at Birth			
Female	896(100%)		
Male	0(0%)		
Identifies As			
Female	895(99.9%)		
Male	0(0%)		
Two-Spirit	1(0.1%)		

Non-Binary	0(0.0%)		
Other	0(0.0%)		
Age		64.2(7.3)	41-88
Total Years of Education		15.5(5.0)	
Age of Menopausal Onset		49.4(6.5)	12-62
Type of Menopause			
Spontaneous	667(74.4%)	51.3(4.2)	12-62
Hysterectomy and/or	162(18.1%)	42.0(8.7)	12-62
Oophorectomy			
Other Medical Reasons	67(7.5%)	47.5(5.2)	30-58
Experience of Perimenopausal	666(74.3%)		
Symptoms			
HT Use	166(24.9%)		
Estradiol	41(6.2%)		
Conjugated Estrogens	34(5.1%)		
Combination Estrogen-	73(11.0%)		
Progesterone			
Combination Estrogen-	18(2.7%)		
Progestin			
Progestin or Unnamed HT Use			
Progestin	12(1.8%)		
Unnamed HT	47(7.1%)		
Origin			

North American	444(49.6%)	
First Nation	17(3.8%)	
Metis	12(2.7%)	
Inuit	0(0.0%)	
European	764(85.3%)	
Caribbean	7(0.8%)	
South American	6(0.7%)	
African	7(0.8%)	
Asian	18(2.0%)	
Oceania	3(0.3%)	

Abbreviations: HT, hormone therapies

From the list of 11 menopausal symptoms, participants endorsed a range of 0 to 10 (see Figure 2) and reported a mean menopausal symptom burden of 3.7 ± 2.8 (spontaneous = 3.8 ± 2.8 , due to surgical or medical reasons = 3.5 ± 2.8). The most frequently endorsed perimenopausal symptom was hot flashes (n = 583, 88%) followed by night sweats (n = 496, 70%). The least endorsed perimenopausal symptoms were chills (n = 92, 14%) and other symptoms not listed (n = 31, 5%).

Figure 2. Reported perimenopausal symptoms.

Frequency comparison of participant endorsed and not endorsed perimenopausal symptoms, reported from the CAN-PROTECT fertility and menopause questionnaire. Red bars indicate the number of participants who endorsed a perimenopausal symptom, while grey bars indicate the number of participants who did not.

Everyday cognition and Mild Behavioral Impairment

Collectively, participants reported a mean ECog-II total score of 11.1±10.5, with a range of 0 to 88. Mean MBI-C total symptom burden score was 5.4±7.6, with a range of 0 to 65.

Menopausal symptom burden and cognitive function

Menopausal symptom burden was associated with poorer cognitive function, according to the results of the negative binomial regression model (see Table 2 and Figure 3). Every additional menopausal symptom was associated with a 5.37% higher ECog-II total score, indicating more consistent symptoms of cognitive dysfunction (95%CI[2.85, 7.97], p<.001). Neither the type of menopause (b=2.78%, 95%CI[-13.10, 21.91], p=.75) nor the age of menopausal onset (b=-1.05%, 95%CI[-2.13, 0.013], p=.068) was significantly associated with ECog-II total score. Similarly, neither HT (b=-10.98%, 95%CI[-25.33, 6.54], p=.20) nor use of progestin or unnamed HT (b=16.93%, 95%CI[-10.93, 56.13], p=.27) were significantly associated with ECog-II total score.

Table 2. ECog-II total score associations

Variable	b%[95% CI]	p	
Menopausal Symptom Burden	5.37%[2.85, 7.97]	<0.001*	
Type of Menopause	2.78%[-13.10, 21.91]	0.75	
Age of Menopausal Onset	-1.05%[-1.17, 0.59]	0.068	
Progestin or Unnamed HT Use	16.93%[-10.93, 56.13]	0.27	
HT Use	-10.98%[-25.33, 6.53]	0.20	
Interaction Variables			
Age of Menopausal Onset	0.26%[-0.26, 0.40]	0.69	
Progestin or Unnamed HT Use	2.95%[-8.83, 16.87]	0.43	
HT Use	0.50%[-7.30, 9.09%]	0.13	

* Indicates a significant association Abbreviations: ECog-II, revised Everyday Cognition Scale; HT, hormone therapies; CI, confidence intervals Figure 3. ECog-II total score associations. Negative-binomial regression coefficient plot of the relationship between menopausal symptom burden (predictor variable) and ECog-II total score (outcome variable). Lines indicate the 95% confidence intervals for the estimate. Predictor variables whose confidence intervals cross the reference line at 1.00 are not significant. Significant predictor variables are indicated with an asterisk. None of age of menopausal onset (b=0.070%, 95%CI[-0.26, 0.40], p=.69), use of HT (b=0.50%, 95%CI[-7.30, 9.09], p=.13), or use of progestin or unnamed HT (b=2.95%,95%CI[-8.83, 16.87], p=.48) moderated the relationship between menopausal symptom burden and ECog-II total score. Menopausal symptom burden and Mild Behavioral Impairment Menopausal symptom burden was associated with greater MBI symptom burden, f according to the results of the zero-inflated negative binomial regression (see Table 3 and Figure 4). Every additional menopausal symptom was associated with a 6.09% higher MBI-C total score (95%CI[2.50, 9.80], p<.001), indicating more consistent symptoms of MBI. HT use was associated with a 26.90% lower MBI-C total score (95%CI[-43.35, -5.67], p<.016). None of type of menopause (b=4.56%, 95%CI[-18.17, 33.60], p=.72), age of menopausal onset (b=-0.83%, 95%CI[-2.36, 0.74], p=.30), or use of progestin or unnamed HT (b=-19.12%, 95%CI[-44.60, 18.07], p=.27) were significantly associated with MBI-C total score.

Table 3. MBI-C total score associations

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

Variable	b%[95%CI]	p
Menopausal Symptom Burden	6.09%[2.50, 9.80]	<0.001*
Type of Menopause	4.56%[-18.17, 33.60]	0.72
Age of Menopausal Onset	-0.83%[-2.36, 0.74]	0.30
Progestin or Unnamed HT Use	-19.12%[-44.60, 18.07]	0.27
HT Use	-26.90%[-43.35, -5.67]	0.016*
Interaction Variables		
Age of Menopausal Onset	-0.066%[-0.50, 0.37]	0.77
Progestin or Unnamed HT Use	7.22%[-8.01, 25.63]	0.37
HT Use	-0.20%[-11.21, 12.17]	0.97

^{*} Indicates a significant association

Abbreviations: MBI-C, Mild Behavioral Impairment Checklist; HT, hormone therapies; CI, confidence intervals

Figure 4. MBI-C total symptom score associations.

Zero-inflated negative-binomial regression coefficient plot of the relationship between menopausal symptom burden (predictor variable) and MBI-C total score (outcome variable). The count model coefficient estimates are indicated by the conditional title, while the zero-inflated coefficient estimates are indicated by the zero-inflated title. Lines indicate the 95% confidence intervals for the estimate. Predictor variables whose confidence intervals cross the reference line at 1.00 are not significant and indicated by the colour red. Significant predictor variables are indicated by the colour blue.

Despite the main effect of HT use and lower MBI-C total score, use of HT did not moderate the relationship between menopausal symptom burden and MBI-C total score (b=-

0.20%, 95%CI[-11.21, 12.17], p=.97). Similarly, neither the age of menopausal onset (b=0.066%, 95%CI[-0.50, 0.37], p=.77) nor use of progestin or unnamed HT (b=7.22%, 95%CI[-8.01, 25.63], p=.37) significantly moderated the relationship between menopausal symptom burden and MBI-C total score.

The experience of menopause can include persistent changes in cognitive function and

Discussion

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

behaviour, which may extend into later life and identify those at greater risk for incident dementia. In this study, we showed that greater menopausal symptom burden was associated with significantly poorer cognitive function and greater MBI symptom burden, adjusted for age, education, age of menopausal onset, type of menopause, use of HT, and use of progestin or unnamed HT. While use of either HT or progestins or unnamed HT was not significantly associated with changes in cognitive function, use of HT was associated with significantly fewer MBI symptoms. Subsequent analyses revealed that age of menopausal onset and use of HT or progestin or unnamed HT did not moderate the observed associations between menopausal symptom burden and cognition or MBI. Changes in cognitive function are a defining feature of the normal aging process in females and males⁶⁰. However, Alzheimer disease starts long before diagnosis and understanding the earliest factors influencing its progression is critical. Therefore, identifying later-life emergent and persistent changes in cognitive function may aid in assessing risk for dementia. Other studies have shown that select perimenopausal symptoms may be associated with cognitive changes. For instance, evidence from cross-sectional studies have found perimenopausal females who experienced specific symptoms were more likely to report poorer cognitive function in the domains of attention^{24,26}, working memory^{8,23}, verbal memory^{18,21,24},

visuo-spatial skills²⁴, and processing speed^{26,27}. However, whether the additive effect of experiencing more than one menopausal symptom is related to later-life changes in cognitive function had yet to be determined. Our first analysis suggests that the degree of menopausal symptom burden (i.e., greater number of menopausal symptoms) is indeed associated with poorer mid-to-later life cognitive function. Thus, our findings are novel in that they show not only are specific menopausal symptoms related to changes in cognitive function, but the overall number of menopausal symptoms experienced are important as well.

Few studies have investigated the association between multiple perimenopausal symptoms (i.e., menopausal symptom burden) with risk of dementia as determined by both cognitive and behavioural changes. Studies have shown that select perimenopausal symptoms may be related to AD-related neuropathological changes in the brain. For instance, perimenopausal females who experienced night sweats (i.e., a vasomotor symptom) had greater brain amyloid beta pathology than perimenopausal females who did not⁶¹. While such findings suggest that perimenopausal symptoms may be related to risk of dementia, given that participants in our study reported an average of 3.7 perimenopausal symptoms, it is important to recognize that measuring only one symptom does not tell the whole story; symptomatic perimenopausal females may experience more than one symptom at a time. The experience of multiple menopausal symptoms may estimate dementia risk in a way not accounted for by analysis of a single menopausal symptom, as evidenced by the dose effect we found. Further, to identify whether the experience of multiple menopausal symptoms is related to dementia risk, both markers of cognitive change and behavioural change should be used.

While changes in cognitive function may act as one marker of dementia risk, later-life emergent and persistent changes in behaviour consistent with MBI are another marker, which

complements cognition³⁶. Several studies have linked MBI with cognitive decline and dementia. A longitudinal study of MBI in cognitively normal older persons, using sex-stratified analyses, described MBI effects for cognitive decline in both females and males⁶². In a mixed sex study that explored progression to dementia in a neuropsychiatry clinic sample, participants with MBI had a higher progression-rate to dementia than those with psychiatric disorders. Additionally, in both female and male patients with MCI, those with comorbid MBI had a higher progression rate than those without⁶³. These findings have been replicated in a geriatric psychiatry clinic sample⁴⁷ and in observational cohorts of older adults with normal cognition and subjective cognitive decline^{37,64,65}, with MCI^{37,38}, and in mixed cognitively unimpaired/MCI samples^{42,44-46}. These findings support MBI as an effect modifier in the relationship between cognitive function and incident dementia. Our cross-sectional study shows that this may also be the case in a cohort of females, alone. This emerging body of evidence highlights the importance of including assessment of behavioural changes, consistent with MBI, in conjunction with the wellestablished practice of determining cognitive status in dementia risk assessment⁶⁶. Despite the importance of the link, sparse research has explored the relationship between menopause and MBI and none exploring dose effects, i.e., number of perimenopausal symptoms and later-life MBI symptoms (let alone cognitive symptoms). Our findings of a dose effect encourage further investigations of this link. Why some perimenopausal females and not others may experience symptoms has not been elucidated; however, recent evidence suggests that differences in the experience of menopause, such as in menopausal symptoms, may be linked to physiological stressors¹⁰⁻¹³. Estradiol is known to lead to synapse formation, neurite outgrowth, and neurogenesis, all of which decline in neurodegenerative diseases and dementia. However, in menopause, estradiol

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

naturally declines^{6,10}. Thus, the experience of menopausal symptoms may act as an indicator of how well females tolerate estradiol changes 16,67-70. Indeed, in a 10-year longitudinal study of Vitamin D exposure and incident dementia, the effect of Vitamin D for lower hazard of incident dementia was greater in females, thought to be secondary to the role of estrogen in activating Vitamin D⁶⁷. This evidence suggests two possible mechanisms for how menopause may be related to risk for AD. The first mechanism may be the direct effect of estrogens on neurons 17,68 with greater decline in estrogens increasing risk for cognitive decline and dementia. The second mechanism may be indirect and dependent on how body systems other than the brain in individual females respond to estrogen decline, modifying risk of developing AD-related neuropathological changes in the brain. Although further exploration is required, it is likely that both mechanisms contribute to the association between estradiol loss, perimenopausal symptoms, and AD. HT are amongst the most effective treatments for alleviating perimenopausal symptoms by mitigating menopause-related estradiol decline^{8,69}. Thus, they are essential to understanding physiological responses to menopause. Given that estrogens have been shown to mitigate against AD cognitive and brain changes ^{16,68,70-73}, some research speculates they may help to reduce to the risk of dementia^{8,16,32,74}. Despite this hypothesis, evidence remains conflicted as studies continue to report mitigating^{8,32,33}, neutral^{34,35}, and harmful^{35,75,76} associations with dementia risk for females. Additionally, factors such as the age at start of therapy, duration, genetic interactions, and type of HT likely complicate the association, making the relationship highly complex and variable person to person^{8,16,33,71,74}. In our cognitive analysis, we found neither direct nor interaction effects of HT for cognitive function in females independent of menopause type or age at menopause. These

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

findings contradict studies that support the role of HT to ameliorate cognitive decline in females with perimenopausal symptoms ^{8,32,33}. This may be due to the highly variable response of individual females to estradiol loss and replacement and the direction of effect in our study does suggest potential enhancement of cognitive performance. Indeed, our behavioural analysis revealed a main effect for HT and behaviour without an interaction effect, suggesting potential links between HT taken during perimenopause and subsequent behavioural risk for dementia in our cohort. Although research remains sparse, other studies show that the use of HT has been implicated in the improvement of behavioural symptoms during perimenopause, including emotional symptoms ^{75,77-80}. One study found that compared to females who experienced no symptoms of menopause, perimenopausal females who used HT had improved depression severity, but only in those who also experienced hot flashes suggesting that the beneficial effects were due to treatment of the hot flashes⁷⁷. Altogether, these findings suggest that HT may mitigate MBI symptoms differently from cognitive symptoms.

There are several limitations to this study. First, the cross-sectional design of the study limits conclusions about causality. To determine temporal relationships, longitudinal data are required, ideally with biomarker data (i.e., blood estradiol, phosphorylated-tau, and amyloid beta levels) to further explore potential mechanisms. Second, menopausal symptom burden was operationalized objectively as a symptom count, (i.e., number of menopausal symptoms) rather than severity, which might be more subjective. Nonetheless, recent evidence suggests that menopausal symptom severity is associated with poorer cognitive performance²⁴. Additional research is required to incorporate severity into symptom count, to explore these relationships further. Third, sample size limitations precluded analyses of differences between types and formulations of HT and progestogens. A growing number of studies suggest that 17β-estradiol

HT may exert the greatest of neuroprotective effects on cognitive function and risk for AD as compared to other HT estrogens^{81,82}. As we did not find a significant association of HT with cognitive function, it may be that combining different HT estrogens into one group skewed the results. As CAN-PROTECT data accumulate, we may be able to address this limitation in the future. Nonetheless, there are also multiple strengths to this study. The experience of menopause and its association with dementia is highly complex and likely influenced by several variables such as type of menopause, age of onset, and use of HT and progestogens^{8,16,33,71,74}. Our study included each of these variables to represent more accurately the experience of menopause. Finally, contributing to the novelty of our study, we included behaviour, operationalized as the validated construct of MBI to assess risk. Together, changes in cognitive function and behaviour represent two important markers for risk of dementia. Therefore, broadening our understanding of how the experience of menopause may be associated with both cognition and behaviour could have clinical applications for risk for incident dementia.

Conclusions

In conclusion, this study has demonstrated that recalled greater menopausal symptom burden is associated with poorer current cognitive function and greater current MBI symptom burden in mid-to-late life. Use of HT control may help to mitigate MBI symptoms more than cognitive symptoms. These findings suggest menopausal symptom burden may predict susceptibility to dementia, as evidenced by greater cognitive and behavioural factors in those with greater menopausal symptom burden.

Acknowledgements

- 378 All authors contributed to the study design, data acquisition, data analysis and interpretation, and
- manuscript revisions. All authors gave approval for the final submission.

380 REFERENCES

- Nichols E, Steinmetz JD, Vollset SE, et al. Estimation of the global prevalence of
- dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of
- 384 Disease Study 2019. *The Lancet Public Health*. 2022;7(2):e105-e125.
- 385 2. Subramaniapillai S, Almey A, Rajah MN, Einstein G. Sex and gender differences in
- cognitive and brain reserve: Implications for Alzheimer's disease in women. *Frontiers in*
- 387 *Neuroendocrinology*. 2021;60:100879.
- 388 3. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and
- vascular dementia: The EURODEM Studies. *Neurology*. 1999;53(9):1992-1992.
- 390 4. Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz M. Differences
- between women and men in incidence rates of dementia and Alzheimer's disease. *Journal of Alzheimer's disease*. 2018;64(4):1077-1083.
- 393 5. Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer's disease:
- assessing sex and gender differences. *Clinical epidemiology*. 2014:37-48.
- 395 6. Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs,
- 396 symptoms, and management options. *The Journal of Clinical Endocrinology & Metabolism*.
- 397 2021;106(1):1-15.


- 398 7. Edwards H, Duchesne A, Au AS, Einstein G. The many menopauses: searching the
- 399 cognitive research literature for menopause types. *Menopause (New York, NY)*. 2019;26(1):45.
- 400 8. Conde DM, Verdade RC, Valadares AL, Mella LF, Pedro AO, Costa-Paiva L.
- Menopause and cognitive impairment: A narrative review of current knowledge. *World Journal* of Psychiatry. 2021;11(8):412.
- 403 9. Al-Azzawi F, Palacios S. Hormonal changes during menopause. *Maturitas*.
- 404 2009;63(2):135-137.
- 405 10. Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management.
- 406 Endocrinology and Metabolism Clinics. 2015;44(3):497-515.
- 407 11. Lobo RA, Davis SR, De Villiers T, et al. Prevention of diseases after menopause.
- 408 *Climacteric*. 2014;17(5):540-556.
- 409 12. Faleschini S, Tiemeier H, Rifas-Shiman SL, et al. Longitudinal associations of
- 410 psychosocial stressors with menopausal symptoms and well-being among women in midlife.
- 411 *Menopause*. 2022;29(11):1247-1253.
- 412 13. Simpson EE. Stress and Coping in the Menopause. *Stress: Concepts, cognition, emotion,*
- 413 *and behavior*. Elsevier; 2016:451-455.
- 414 14. Farias ST, Mungas D, Reed BR, et al. The measurement of everyday cognition (ECog):
- scale development and psychometric properties. *Neuropsychology*. 2008;22(4):531.
- 416 15. Silverberg NB, Ryan LM, Carrillo MC, et al. Assessment of cognition in early dementia.
- 417 *Alzheimer's & Dementia*. 2011;7(3):e60-e76.
- 418 16. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, estrogen, and dementia: a 2014
- 419 update. *Molecular and cellular endocrinology*. 2014;389(1-2):7-12.


- 420 17. Rocca W, Bower J, Maraganore D, et al. Increased risk of cognitive impairment or
- dementia in women who underwent oophorectomy before menopause. *Neurology*.
- 422 2007;69(11):1074-1083.
- 423 18. Maki PM, Rubin LH, Savarese A, et al. Stellate ganglion blockade and verbal memory in
- midlife women: evidence from a randomized trial. *Maturitas*. 2016;92:123-129.
- 425 19. Maki P, Thurston R. Menopause and brain health: hormonal changes are only part of the
- 426 story. Front Neurol. 2020; 11: 562275. 2020.
- 427 20. Gava G, Orsili I, Alvisi S, Mancini I, Seracchioli R, Meriggiola MC. Cognition, mood
- and sleep in menopausal transition: the role of menopause hormone therapy. *Medicina*.
- 429 2019;55(10):668.
- 430 21. Maki PM, Drogos LL, Rubin LH, Banuvar S, Shulman LP, Geller SE. Objective hot
- flashes are negatively related to verbal memory performance in midlife women. *Menopause*
- 432 (New York, NY). 2008;15(5):848.
- 433 22. Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a
- 434 systematic review and meta-analysis. The Journal of steroid biochemistry and molecular
- 435 biology. 2014;142:90-98.
- 436 23. Hampson E. Estrogens, aging, and working memory. *Current psychiatry reports*.
- 437 2018;20:1-9.
- 438 24. Kaur M, Kaur M. Is cognitive performance of women sensitive to the severity of
- 439 menopausal symptoms? *Menopause*. 2022;29(2):170-177.
- 440 25. Fuh J-L, Wang S-J, Lu S-R, Juang K-D, Chiu LM. The Kinmen women-health
- investigation (KIWI): a menopausal study of a population aged 40–54. *Maturitas*.
- 442 2001;39(2):117-124.
- 26. Zhu C, Thomas N, Arunogiri S, Gurvich C. Systematic review and narrative synthesis of
- cognition in perimenopause: The role of risk factors and menopausal symptoms. *Maturitas*.
- 445 2022;164:76-86.
- 446 27. Jaff NG, Rubin LH, Crowther NJ, Norris SA, Maki PM. Menopausal symptoms,
- 447 menopausal stage and cognitive functioning in black urban African women. *Climacteric*.
- 448 2020;23(1):38-45.
- 449 28. Huang W, Jiang S, Geng L, Li C, Tao M. Correlation between menopausal symptoms
- and everyday cognition in Chinese (peri) menopausal women. *Gynecological Endocrinology*.
- 451 2021;37(7):655-659.
- 452 29. Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of
- premature or early menopause and considerations for management. Climacteric. 2015;18(4):483-
- 454 491.
- 455 30. Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petridou ET. Surgical
- 456 menopause in association with cognitive function and risk of dementia: a systematic review and
- 457 meta-analysis. *Psychoneuroendocrinology*. 2019;106:9-19.
- 458 31. Wedatilake Y, Myrstad C, Tom S, Strand B, Bergh S, Selbæk G. Female Reproductive
- 459 Factors and Risk of Mild Cognitive Impairment and Dementia: The HUNT Study. *The Journal*
- *of Prevention of Alzheimer's Disease.* 2024:1-10.
- 461 32. Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease
- dementia: new findings from the Cache County Study. *Neurology*. 2012;79(18):1846-1852.
- 463 33. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical
- 464 time. Jama. 2002;288(17):2170-2172.


- 465 34. Seshadri S, Zornberg GL, Derby LE, Myers MW, Jick H, Drachman DA.
- 466 Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. *Archives of*
- 467 *neurology*. 2001;58(3):435-440.
- 468 35. Imtiaz B, Tuppurainen M, Rikkonen T, et al. Postmenopausal hormone therapy and
- 469 Alzheimer disease: A prospective cohort study. *Neurology*. 2017;88(11):1062-1068.
- 470 36. Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of
- emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimer's
- 472 & Dementia. 2016;12(2):195-202.
- 473 37. Ismail Z, McGirr A, Gill S, Hu S, Forkert ND, Smith EE. Mild behavioral impairment
- and subjective cognitive decline predict cognitive and functional decline. *Journal of Alzheimer's*
- 475 disease. 2021;80(1):459-469.
- 476 38. McGirr A, Nathan S, Ghahremani M, Gill S, Smith EE, Ismail Z. Progression to dementia
- or reversion to normal cognition in mild cognitive impairment as a function of late-onset
- 478 neuropsychiatric symptoms. *Neurology*. 2022;98(21):e2132-e2139.
- 479 39. Rouse HJ, Ismail Z, Andel R, Molinari VA, Schinka JA, Small BJ. Impact of mild
- behavioral impairment on longitudinal changes in cognition. *The Journals of Gerontology:*
- 481 *Series A.* 2024;79(1):glad098.
- 482 40. Kan CN, Cano J, Zhao X, Ismail Z, Chen CL-H, Xu X. Prevalence, Clinical Correlates,
- 483 Cognitive Trajectories, and Dementia Risk Associated With Mild Behavioral Impairment in
- 484 Asians. The Journal of Clinical Psychiatry. 2022;83(3):40123.
- 485 41. Wolfova K, Creese B, Aarsland D, et al. Gender/sex differences in the association of mild
- behavioral impairment with cognitive aging. Journal of Alzheimer's Disease. 2022;88(1):345-
- 487 355.
- 488 42. Ghahremani M, Wang M, Chen H-Y, et al. Plasma Phosphorylated Tau at Threonine 181
- and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. *Neurology*.
- 490 2023;100(7):e683-e693.
- 491 43. Ismail Z, Leon R, Creese B, Ballard C, Robert P, Smith EE. Optimizing detection of
- 492 Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral
- impairment in ADNI and MEMENTO. *Molecular Neurodegeneration*. 2023;18(1):50.
- 494 44. Ismail Z, Ghahremani M, Amlish Munir M, Fischer CE, Smith EE, Creese B. A
- longitudinal study of late-life psychosis and incident dementia and the potential effects of race
- and cognition. *Nature Mental Health*. 2023;1(4):273-283.
- 497 45. Ebrahim IM, Ghahremani M, Camicioli R, Smith EE, Ismail Z. Effects of race, baseline
- 498 cognition, and APOE on the association of affective dysregulation with incident dementia: A
- 499 longitudinal study of dementia-free older adults. *Journal of Affective Disorders*. 2023;332:9-18.
- 500 46. Vellone D, Ghahremani M, Goodarzi Z, Forkert ND, Smith EE, Ismail Z. Apathy and
- APOE in mild behavioral impairment, and risk for incident dementia. Alzheimer's & Dementia:
- 502 Translational Research & Clinical Interventions. 2022;8(1):e12370.
- 503 47. Matsuoka T, Ismail Z, Narumoto J. Prevalence of mild behavioral impairment and risk of
- dementia in a psychiatric outpatient clinic. *Journal of Alzheimer's Disease*. 2019;70(2):505-513.
- Naude JP, Gill S, Hu S, et al. Plasma neurofilament light: a marker of neurodegeneration
- in mild behavioral impairment. *Journal of Alzheimer's disease*. 2020;76(3):1017-1027.
- 507 49. Matuskova V, Ismail Z, Nikolai T, et al. Mild behavioral impairment is associated with
- atrophy of entorhinal cortex and hippocampus in a memory clinic cohort. Frontiers in aging
- 509 *neuroscience*. 2021;13:643271.

- 510 50. Ghahremani M, Nathan S, Smith EE, McGirr A, Goodyear B, Ismail Z. Functional
- 511 connectivity and mild behavioral impairment in dementia-free elderly. *Alzheimer's & Dementia*:
- 512 Translational Research & Clinical Interventions. 2023;9(1):e12371.
- 513 51. Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizel LP, Bennett DA. The natural
- 514 history of cognitive decline in Alzheimer's disease. *Psychology and aging*. 2012;27(4):1008.
- 515 52. Hall CB, Lipton RB, Sliwinski M, Stewart WF. A change point model for estimating the
- onset of cognitive decline in preclinical Alzheimer's disease. *Statistics in medicine*.
- 517 2000;19(11-12):1555-1566.
- 518 53. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive
- emergence of the clinical symptoms. *Annals of Neurology: Official Journal of the American*
- *Neurological Association and the Child Neurology Society.* 2008;64(5):492-498.
- 521 54. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from
- healthy aging to Alzheimer disease. *Archives of neurology*. 2009;66(10):1254-1259.
- 523 55. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory
- impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease.
- *Journal of the International Neuropsychological Society*. 2008;14(2):266-278.
- 526 56. Ismail Z, Guan DX, Vellone D, et al. The Canadian platform for research online to
- 527 investigate health, quality of life, cognition, behaviour, function, and caregiving in aging (CAN-
- 528 PROTECT): study protocol, platform description, and preliminary analyses. *medRxiv*.
- 529 2023:2023.12.16.23300094. doi:10.1101/2023.12.16.23300094
- 530 57. Farias ST, Weakley A, Harvey D, Chandler J, Huss O, Mungas D. The measurement of
- 531 Everyday Cognition (ECog): revisions and updates. *Alzheimer disease and associated disorders*.
- 532 2021;35(3):258.
- 533 58. Ismail Z, Agüera-Ortiz L, Brodaty H, et al. The Mild Behavioral Impairment Checklist
- 534 (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. *Journal of*
- 535 *Alzheimer's disease*. 2017;56(3):929-938.
- 536 59. Hu S, Patten S, Charlton A, et al. Validating the Mild Behavioral Impairment Checklist in
- a Cognitive Clinic: Comparisons With the Neuropsychiatric Inventory Questionnaire. J Geriatr
- 538 Psychiatry Neurol. Mar 2023;36(2):107-120. doi:10.1177/08919887221093353
- 539 60. Kester JD, Benjamin AS, Castel AD, Craik FI. Memory in elderly people. *Handbook of*
- 540 *memory disorders*. 2002;2:543-567.
- 541 61. Thurston RC, Pauline M, Chang Y, et al. Menopausal Vasomotor Symptoms and Plasma
- 542 Alzheimer's Disease Biomarkers. *American Journal of Obstetrics and Gynecology*. 2023;
- 543 62. Wolfova K, Creese B, Aarsland D, et al. Gender/Sex Differences in the Association of
- Mild Behavioral Impairment with Cognitive Aging. J Alzheimers Dis. May 16 2022;88(1):345-
- 545 355. doi:10.3233/JAD-220040
- 546 63. Taragano FE, Allegri RF, Heisecke SL, et al. Risk of conversion to dementia in a mild
- behavioral impairment group compared to a psychiatric group and to a mild cognitive
- impairment group. Journal of Alzheimer's Disease. 2018;62(1):227-238.
- 549 64. Mallo SC, Ismail Z, Pereiro AX, et al. Assessing mild behavioral impairment with the
- mild behavioral impairment checklist in people with subjective cognitive decline. *International*
- *psychogeriatrics*. 2019;31(2):231-239.
- 552 65. Creese B, Brooker H, Ismail Z, et al. Mild behavioral impairment as a marker of
- cognitive decline in cognitively normal older adults. The American Journal of Geriatric
- 554 Psychiatry. 2019;27(8):823-834.

- 555 66. Ismail Z, Black SE, Camicioli R, et al. Recommendations of the 5th Canadian Consensus
- 556 Conference on the diagnosis and treatment of dementia. *Alzheimer's & Dementia*.
- 557 2020;16(8):1182-1195.
- 558 67. Ghahremani M, Smith EE, Chen HY, Creese B, Goodarzi Z, Ismail Z. Vitamin D
- supplementation and incident dementia: Effects of sex, APOE, and baseline cognitive status.
- 560 Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2023;15(1):e12404.
- Norbury R, Cutter WJ, Compton J, et al. The neuroprotective effects of estrogen on the aging brain. *Experimental gerontology*. 2003;38(1-2):109-117.
- 563 69. Kaunitz AM, Manson JE. Management of menopausal symptoms. *Obstetrics and gynecology*. 2015;126(4):859.
- 565 70. C Correia S, X Santos R, Cardoso S, et al. Effects of estrogen in the brain: is it a
- neuroprotective agent in Alzheimer's disease? *Current aging science*. 2010;3(2):113-126.
- 71. Pertesi S, Coughlan G, Puthusseryppady V, Morris E, Hornberger M. Menopause,
- cognition and dementia—A review. *Post reproductive health*. 2019;25(4):200-206.
- 72. Rahman A, Schelbaum E, Hoffman K, et al. Sex-driven modifiers of Alzheimer risk: a
- multimodality brain imaging study. *Neurology*. 2020;95(2):e166-e178.
- 571 73. Uddin MS, Rahman MM, Jakaria M, et al. Estrogen signaling in Alzheimer's disease:
- 572 molecular insights and therapeutic targets for Alzheimer's dementia. *Molecular Neurobiology*.
- 573 2020;57:2654-2670.
- 574 74. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women:
- effects on cognitive function and dementia. *Jama*. 1998;279(9):688-695.
- 576 75. Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition
- and mood in recently postmenopausal women: findings from the randomized, controlled
- 578 KEEPS-cognitive and affective study. *PLoS medicine*. 2015;12(6):e1001833.
- 579 76. Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, et al. Use of postmenopausal
- hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. *bmj*.
- 581 2019;364
- Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms
- in postmenopausal women after receiving hormone therapy: results from the Heart and
- Estrogen/Progestin Replacement Study (HERS) trial. *Jama*. 2002;287(5):591-597.
- 585 78. Toffol E, Heikinheimo O, Partonen T. Hormone therapy and mood in perimenopausal
- and postmenopausal women: a narrative review. *Menopause*. 2015;22(5):564-578.
- 587 79. Kirkham C, Hahn P, VAN VUG D, Carmichael J, Reid R. A randomized, double-blind,
- placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in
- hormone replacement therapy. *Obstetrics & Gynecology*. 1991;78(1):93-97.
- 590 80. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined
- estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal
- 592 women. Maturitas. 2003;44(2):157-163.
- 81. Baker LD, Sambamurti K, Craft S, et al. 17β-Estradiol reduces plasma Aβ40 for HRT-
- naive postmenopausal women with Alzheimer disease: a preliminary study. *The American*
- *journal of geriatric psychiatry*. 2003;11(2):239-244.
- 596 82. Petrovska S, Dejanova B, Jurisic V. Estrogens: mechanisms of neuroprotective effects.
- *Journal of Physiology and Biochemistry*. 2012;68:455-460.







MBI-C Total Score

